The FDA on October 8, 2025, approved LIBTAYO® for the adjuvant treatment of adults with Cutaneous Squamous Cell Carcinoma (CSCC) at high risk of recurrence after surgery and radiation. LIBTAYO® is a product of Regeneron Pharmaceuticals Inc.
Bottom Ad
Advertisement
Subscribe
